Abstract
At the International Conference on A Therapeutic Trials in Multiple Sclerosis, it was decided that standardized working protocols should be designed for use by investigators planning clinical trials in multiple sclerosis (MS). Because a detailed protocol must take into account the local resources of the investigator, the unique properties of the therapeutic agent being tested, and the stage of the illness being treated, it not possible to create one protocol that can be used as is for all clinical trials. Nonetheless, there are a large number of issues that must be addressed in all clinical trials of therapeutic agents in MS. This article addresses those issues in a form that can be used by investigators to construct specific protocols. Depending on the stage of disease, four specific treatment goals might be addressed in a clinical trial of a therapeutic modality in MS. Because many aspects of an MS
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
